, European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies

C. Meffre, L. Strat, Y. Delarocque-astagneau, E. Dubois, F. Antona et al., Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors, J Med Virol, vol.82, pp.546-555, 2010.

C. Brouard, L. Strat, Y. Larsen, C. Jauffret-roustide, M. Lot et al., The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014, PLoS One, vol.10, p.126920, 2015.

E. Delarocque-astagneau, C. Meffre, F. Dubois, C. Pioche, L. Strat et al.,

F. , The impact of the prevention programme of hepatitis C over more than a decade: the French experience, J Viral Hepat, vol.17, pp.435-443, 2010.

C. Brouard, D. Astagneau, E. Meffre, C. Pioche, C. Silvain et al., Trends of hepatitis C screening in France through Rena-VHC and hepatology reference centres surveillance system, Bull Epidemiol Hebd, pp.199-204, 2000.

J. E. Arends, P. A. Kracht, and A. I. Hoepelman,

, Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice, Clin Microbiol Infect, vol.22, pp.846-852, 2016.

S. Chevaliez, L. Poiteau, I. Rosa, A. Soulier, F. Roudot-thoraval et al.,

, Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care, Clin Microbiol Infect, vol.22, pp.459-451, 2016.

B. D. Smith, R. L. Morgan, G. A. Beckett, Y. Falck-ytter, D. Holtzman et al., Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention, Ann Intern Med, vol.157, pp.817-822, 2012.

J. Grebely, M. Bilodeau, J. J. Feld, J. Bruneau, B. Fischer et al., The Second Canadian Symposium on hepatitis C virus: a call to action, Canadian Journal of Gastroenterology, vol.27, pp.627-632, 2013.

, Canadian Liver Foundation. Position statement -hepatitis C testing, 2012.

S. Deuffic-burban, P. Deltenre, M. Buti, T. Stroffolini, J. Parkes et al., Predicted effects of treatment for HCV infection vary among European countries, Gastroenterology, vol.143, pp.974-985, 2012.

S. Deuffic-burban, J. Boursier, V. Leroy, Y. Yazdanpanah, L. Castera et al., Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?, J Hepatol, vol.66, pp.304-312, 2017.

M. Schwarzinger, S. Deuffic-burban, V. Mallet, S. Pol, and G. P. Pageaux,

V. , Lifetime costs attributable to chronic hepatitis C from the French healthcare perspective (Anrs N°12188), J Hepatol, vol.58, pp.21-22, 2013.

A. Cousien, V. C. Tran, S. Deuffic-burban, M. Jauffret-roustide, and J. S. Dhersin,

Y. Yazdanpanah, Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs, Hepatology, vol.63, pp.1090-1101, 2016.

, Prise en charge thérapeutique et suivi de l'ensemble des personnes infectées par le virus de l'hépatite C. Rapport de recommandations 2016: Sous la direction du Pr Daniel Dhumeaux. Sous l'égide de l'ANRS

M. R. Gold, J. E. Siegel, L. B. Russell, and M. C. Weinstein, Cost effectiveness in health and medicine, 1996.

. Has-haute-autorité-de-santé, Guide méthodologique : Choix méthodologiques pour l'évaluation économique à la HAS. Octobre 2011: Haute Autorité de Santé, 2011.

I. Mundi, World GDP -per capita (PPP), p.12, 2018.

, Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO, WHO, 2003.

P. J. Neumann, J. T. Cohen, and M. C. Weinstein, Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold, N Engl J Med, vol.371, pp.796-797, 2014.

S. Deuffic-burban, D. Obach, V. Canva, S. Pol, F. Roudot-thoraval et al.,

, Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case, J Viral Hepat, vol.23, pp.767-779, 2016.

G. Corrao and S. Arico, Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis, Hepatology, vol.27, pp.914-919, 1998.

S. Deuffic-burban, P. Mathurin, S. Pol, C. Larsen, F. Roudot-thoraval et al., Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis, Gut, vol.61, pp.290-296, 2012.

, European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016, J Hepatol, vol.66, pp.153-194, 2017.

A. J. Van-der-meer, B. J. Veldt, J. J. Feld, H. Wedemeyer, J. F. Dufour et al.,

, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, vol.308, pp.2584-2593, 2012.

S. Deuffic-burban, M. Schwarzinger, D. Obach, V. Mallet, S. Pol et al., Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141), J Hepatol, vol.61, pp.7-14, 2014.

. Afef, Recommandations AFEF sur la prise en charge de l'hépatite virale C: Société Française d'Hépatologie, 2017.

, Accès universel aux traitements innovants contre l'hépatite C : Après avoir permis l'accès de tous les malades aux traitements, Marisol Touraine obtient une baisse de prix importante, Ministère des Affaires sociales et de la Santé

J. Chevalier and G. De-pouvourville, Valuing EQ-5D using time trade-off in France, Eur J Health Econ, vol.14, pp.57-66, 2013.

S. Pol, J. Chevalier, S. Branchoux, R. Perry, G. Milligan et al., Health related quality of life and utility values in chronic hepatitis C patients: A cross-sectional study in France, the Uk and Germany (P0747), J Hepatol, vol.62, p.606, 2015.

C. A. Chong, A. Gulamhussein, E. J. Heathcote, L. Lilly, M. Sherman et al.,

, Health-state utilities and quality of life in hepatitis C patients, Am J Gastroenterol, vol.98, pp.630-638, 2003.

, Prise en charge des personnes infectées par les virus de l'hépatite B ou de l'hépatite C

, Sous la direction du Pr Daniel Dhumeaux et sous l'égide de l'ANRS et de l'AFEF, 2014.

J. Bottero, C. Brouard, F. Roudot-thoraval, S. Deuffic-burban, P. Hofliger et al., French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV, Liver Int, vol.36, pp.1442-1449, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01299138

, Synthèse de la recommandation en santé publique -Réévaluation de la stratégie de dépistage de l'infection à VIH en France -Mars, 2017.

V. A. Moyer and U. S. , Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, vol.159, pp.349-357, 2013.

D. B. Rein, B. D. Smith, J. S. Wittenborn, S. B. Lesesne, L. D. Wagner et al., The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings, Ann Intern Med, 2012.

, The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C, Hepatology, vol.20, pp.15-20, 1994.

T. Poynard, V. Ratziu, C. F. Goodman, Z. Mchutchison, J. Albrecht et al., Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c, J Hepatol, vol.34, pp.730-739, 2001.

L. Serfaty, H. Aumaitre, O. Chazouilleres, A. M. Bonnand, and O. Rosmorduc,

, Determinants of outcome of compensated hepatitis C virus-related cirrhosis, Hepatology, vol.27, pp.1435-1440, 1998.

G. Corrao and S. Arico, Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis, Hepatology, vol.27, pp.914-919, 1998.

F. Degos, C. Christidis, N. Ganne-carrié, J. Farmachidi, C. Degott et al.,

, Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death, Gut, vol.47, pp.131-136, 2000.

G. L. Davis, M. J. Alter, H. El-serag, T. Poynard, and L. W. Jennings, Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression, Gastroenterology, vol.138, pp.513-521, 2010.

S. Deuffic-burban, P. Mathurin, S. Pol, C. Larsen, F. Roudot-thoraval et al.,

, Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis, Gut, vol.61, pp.290-296, 2012.

A. Mourad, S. Deuffic-burban, N. Ganne-carrié, T. Renaut-vantroys, and R. I. Bouvier,

. Am, HCC screening in patients with compensated HCV-related cirrhosis aware of their HCV-status improves survival: a modeling approach, Hepatology, vol.59, pp.1471-1481, 2014.

G. D'amico, G. Garcia-tsao, and L. Pagliaro, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, vol.44, pp.217-231, 2006.

A. De and L. Biomédecine, , 2011.

, World Health Organiztion. Global Health Observatory Data Repository, 2013.

A. Maladie, Nomenclature générale des actes professionnels (NGAP) restant en vigueur depuis la décision UNCAM du 11 mars, 2005.

A. Maladie, Classification commune des actes médicaux, 2015.

, Agence Technique de l'Information sur l'Hospitalisation. Manuel des GHM -Version définitive 11g, 2015.

S. Cossais, M. Schwarzinger, S. Deuffic-burban, S. Pol, H. Fontaine et al., EQ-5D utility index in french patients with chronic hepatitis C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage (P0745), J Hepatol, vol.62, p.605, 2015.

J. Chevalier and G. De-pouvourville, Valuing EQ-5D using time trade-off in France, Eur J Health Econ, vol.14, pp.57-66, 2013.

A. Mourad, S. Deuffic-burban, N. Ganne-carrie, T. Renaut-vantroys, R. I. Bouvier et al., Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach, Hepatology, vol.59, pp.1471-1481, 2014.

A. J. Van-der-meer, B. J. Veldt, J. J. Feld, H. Wedemeyer, J. F. Dufour et al.,

, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, vol.308, pp.2584-2593, 2012.

A. Nationale, Hepatitis C screening -populations to be screened and screening procedures. Recommendations of the Experts Committee set up by the ANAES, 2001.

M. Schwarzinger, S. Deuffic-burban, V. Mallet, S. Pol, and G. P. Pageaux,

V. , Lifetime costs attributable to chronic hepatitis C from the French healthcare perspective (Anrs N°12188), J Hepatol, vol.58, pp.21-22, 2013.

, Agence Technique de l'Information sur l'Hospitalisation. Le programme de médicalisation des systèmes d'information en médecine, chirurgie, obstétrique et odontologie, 2015.